Galapagos Awarded €4.4 M Grant for Rheumatoid Arthritis Drug Development
News Jan 17, 2008
Galapagos NV has announced that it has been awarded a €4.4 M grant from the Flanders government through the Institute for the Promotion of Innovation by Science and Technology (IWT). The three-year project entitled "Kinases in Inflammation" aims to accelerate Galapagos' rheumatoid arthritis (RA) programs through clinical Proof of Concept in man.
This project builds on the progress of Galapagos' July 2006 IWT funded project, where new biological models were developed to evaluate the effectiveness of small molecules to treat RA.
The new project will apply these biological models to select compounds for clinical studies. The project also aims to develop and validate biomarkers to monitor disease progression and therapeutic response, which will be applied in the early phases of clinical development.
The grant, which will be distributed over a three-year period, will offset preclinical and phase I/phase IIa clinical costs for Galapagos' RA programs. As part of the project, Galapagos will collaborate with the University of Leuven.
"This grant allows us to accelerate our molecules through preclinical and into phase I and phase IIa development, bringing Galapagos a step closer to delivering novel and effective RA drugs to the patient," said Onno van de Stolpe, Chief Executive Officer of Galapagos.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE